Featured Research

from universities, journals, and other organizations

Role For Gefitinib In Asian Nonsmokers With Lung Cancer Established

Date:
September 16, 2008
Source:
European Society for Medical Oncology
Summary:
The targeted therapy gefitinib should be considered a first-line therapy for nonsmoking Asian patients with adenocarcinoma of the lung, one of the most common types of lung cancer, suggests a presentation at the 33rd Congress of the European Society for Medical Oncology.

The targeted therapy gefitinib should be considered a first-line therapy for non-smoking Asian patients with adenocarcinoma of the lung, one of the most common types of lung cancer, suggests a presentation at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.

Related Articles


Asia has a high proportion of lung cancer patients who are non-smokers, a significant proportion of whom develop a form of cancer known as adenocarcinoma.

"Around 50% to 60% of this population have tumors with mutations in the epidermal growth factor receptor, and we know that patients with such mutations have a significantly better treatment outcome with gefitinib," said researcher Prof. Tony Mok from the Chinese University of Hong Kong.

"Currently, gefitinib and other EGFR tyrosine kinase inhibitors are considered as second line therapy for advanced non-small-cell lung cancers, meaning that the drugs should only be used after cancers fail to respond to the standard cytotoxic chemotherapy."

Prof. Mok's group studied 1,217 lung cancer patients who had never received chemotherapy and had never smoked or were light ex-smokers. Half the group was treated with gefitinib 250 mg/day or a combination of carboplatin and paclitaxel.

Over 22 months of follow-up, the researchers found that gefitinib was more tolerable and resulted in a greater likelihood of response.

"We have demonstrated better treatment outcomes with gefitinib over standard chemotherapy as first-line therapy for this clinically selected population," Prof. Mok said. "Our study has established the role of gefitinib as one of the standard first-line therapies for a clinically selected group of non-/light smokers with adenocarcinoma."


Story Source:

The above story is based on materials provided by European Society for Medical Oncology. Note: Materials may be edited for content and length.


Cite This Page:

European Society for Medical Oncology. "Role For Gefitinib In Asian Nonsmokers With Lung Cancer Established." ScienceDaily. ScienceDaily, 16 September 2008. <www.sciencedaily.com/releases/2008/09/080915121327.htm>.
European Society for Medical Oncology. (2008, September 16). Role For Gefitinib In Asian Nonsmokers With Lung Cancer Established. ScienceDaily. Retrieved March 30, 2015 from www.sciencedaily.com/releases/2008/09/080915121327.htm
European Society for Medical Oncology. "Role For Gefitinib In Asian Nonsmokers With Lung Cancer Established." ScienceDaily. www.sciencedaily.com/releases/2008/09/080915121327.htm (accessed March 30, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, March 30, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins